dr joseph harding dihexa - Enterprise Technology & Transformation Leader | AI & Technology Strategist | Systems Thinker dr joseph harding dihexa 🧠

The sums of the number of unique ASVs per sample were compared across groups, with the unclassified sequences excluded for the observed ASVs

Untreated Controls Preclinical injury models % reduction in healing time Tendon Transection (Rat Achilles model)50% Skin Wound Closure (Alkali burn model)45% Muscle Crush Injury (Rat quadriceps)40% Safety Data Safety Profile from Research What preclinical and early clinical studies report Preclinical Safety Summary LD50Not achieved Acute toxicityNone observed Chronic toxicityNone in 6-month studies Organ toxicityNone detected Human IV pilot (n=2)No adverse effects Cardiac/hepatic/renalNo effects detected Regulatory & Risk Considerations FDA statusUnapproved drug WADA statusBanned since 2022 (S0) Human trialsPhase 1 only Long-term effectsUnknown in humans Pro-angiogenic riskTheoretical unstudied Australia/NZPrescription only No lethal dose was reached in preclinical toxicology studies

BV and melittin treatment led to modifications in the bacterial cell membrane due to membrane integrity loss and cellular shape changes involving cellular deformation

Hormone Research , 53(6), 274-278

Numbness, tingling, or a pins-and-needles sensation